RESUMO
In the prevention and treatment of infectious diseases, mRNA vaccines hold great promise because of their low risk of insertional mutagenesis, high potency, accelerated development cycles, and potential for low-cost manufacture. In past years, several mRNA vaccines have entered clinical trials and have shown promise for offering solutions to combat emerging and re-emerging infectious diseases such as rabies, Zika, and influenza. Recently, the successful application of mRNA vaccines against COVID-19 has further validated the platform and opened the floodgates to mRNA vaccine's potential in infectious disease prevention, especially in the veterinary field. In this review, we describe our current understanding of the mRNA vaccines and the technologies used for mRNA vaccine development. We also provide an overview of mRNA vaccines developed for animal infectious diseases and discuss directions and challenges for the future applications of this promising vaccine platform in the veterinary field.
Assuntos
Controle de Doenças Transmissíveis , Doenças Transmissíveis Emergentes/prevenção & controle , Doenças Transmissíveis/virologia , Vacinas Sintéticas/genética , Vacinas Sintéticas/imunologia , Zoonoses/prevenção & controle , Vacinas de mRNA/genética , Vacinas de mRNA/imunologia , Animais , Doenças Transmissíveis/classificação , Doenças Transmissíveis Emergentes/imunologia , Humanos , Vacinas Sintéticas/análise , Vacinas Sintéticas/classificação , Zoonoses/imunologia , Zoonoses/transmissão , Vacinas de mRNA/análise , Vacinas de mRNA/classificaçãoRESUMO
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the most rapid vaccine development in history, with mRNA vaccines at the forefront of those efforts. Although it is now clear that mRNA vaccines can rapidly and safely protect patients from infectious disease, additional research is required to optimize mRNA design, intracellular delivery and applications beyond SARS-CoV-2 prophylaxis. In this Review, we describe the technologies that underlie mRNA vaccines, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles. We also overview the pipeline of mRNA vaccines against various infectious disease pathogens and discuss key questions for the future application of this breakthrough vaccine platform.
Assuntos
COVID-19/prevenção & controle , Controle de Doenças Transmissíveis , Vacinas Sintéticas , COVID-19/epidemiologia , Ensaios Clínicos como Assunto , Controle de Doenças Transmissíveis/métodos , Controle de Doenças Transmissíveis/tendências , Desenho de Fármacos , Desenvolvimento de Medicamentos/métodos , Humanos , RNA Mensageiro/genética , SARS-CoV-2 , Vacinas Sintéticas/classificação , Vacinas Sintéticas/farmacologia , Vacinas de mRNAAssuntos
Vacinas contra COVID-19/imunologia , COVID-19/prevenção & controle , Reações Cruzadas , SARS-CoV-2/imunologia , Anticorpos Neutralizantes/imunologia , Infecções Assintomáticas , COVID-19/transmissão , Vacinas contra COVID-19/classificação , Vacinas contra COVID-19/provisão & distribuição , Saúde Global , Humanos , Esquemas de Imunização , Mutação , Pandemias/prevenção & controle , SARS-CoV-2/genética , Tempo , Vacinas Sintéticas/classificação , Vacinas Sintéticas/imunologia , Vacinas de mRNARESUMO
OBJECTIVE: To evaluate the kinesis of cellular and humoral immune responses to different kinds of recombinant hepatitis B(rHB) vaccines in the immunized mice. METHODS: At serial time points, the levels of IFN-gamma and IL-2 secreted by spleens mononuclear cells (MNC) of the vaccinated mice were detected by enzyme-linked immunospot methods (ELISPOT) after stimulation in vitro with HBsAg MHC class I peptide S28-39 or HBsAg. The lymphocytotoxicity of the immunized mice were also detected (CTL) by a specific lysis assay and the levels of anti-HBs were measured by the Abbott IMX kit. RESULTS: The peak values of IFN-gamma and IL-2 in vaccinated mice were detected by ELISPOT, 10 - 14 days after immunization. The CTL and the level of IFN-gamma induced by rHB vaccine derived from yeast cells (Hansenula polymorpha) (rHP vaccine) were significantly higher than the other two vaccines (P < 0.05). The maximum lysis of CTL appeared in the vaccinated mice on day 10 after immunization, with the percentage of 39.8%. The levels of IL-2 induced by rHP vaccine were significantly higher than the other two vaccines (P < 0.05). However, the IL-2 levels in the rSC (saccharomyces cerevisiae) vaccine group were higher as compared with the rCHO vaccine group at day 7 and day 14 (7 d t = 4.595, P = 0.001 < 0.05; 14 d t = 5.721, P = 0.000 < 0.05) after immunization. The cellular immune response to the rHP vaccine was the strongest while it was the lowest to the rCHO vaccine at day 7 after immunization. The sero-positive rates and the titers of anti-HBs in the vaccinated mice increased with time after vaccination. The titers of anti-HBs in the rCHO vaccine group at day 7 were similar to the rSC vaccine group, but significantly higher than that of the rHP vaccine group (P = 0.044 < 0.05). The anti-HBs titers of the rCHO vaccine group at day 14 were significantly higher as compared to the rSC (P = 0.012 < 0.05) and rHP (P = 0.009 < 0.05) vaccine groups. CONCLUSION: The immune responses induced by the three kinds of rHB vaccines were different in their patterns and levels. According to the intensity of early cellular immune response, the two yeast HB vaccines were superior to the rCHO vaccine, especially to the rHP vaccine. In contrast, the rCHO vaccine induced early seroconversion and high levels of anti-HBs.
Assuntos
Citotoxicidade Imunológica/imunologia , Vacinas contra Hepatite B/imunologia , Animais , Anticorpos Antivirais/sangue , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Vacinas contra Hepatite B/classificação , Imunidade Celular , Imunidade Humoral , Interferon gama/imunologia , Interleucina-2/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Linfócitos T Citotóxicos/imunologia , Vacinas Sintéticas/classificação , Vacinas Sintéticas/imunologiaAssuntos
Humanos , Masculino , Feminino , Infecções Tumorais por Vírus/prevenção & controle , Infecções por Papillomavirus/prevenção & controle , Neoplasias do Colo do Útero/prevenção & controle , Papillomaviridae , Vacinas Sintéticas/normas , Imunoterapia Ativa , Vacinas Sintéticas/administração & dosagem , Vacinas Sintéticas/classificação , Vacinas SintéticasAssuntos
DNA Recombinante , Vetores Genéticos , Proteínas Recombinantes/imunologia , Vacinação/métodos , Vacinas Sintéticas , Animais , Células Cultivadas/virologia , DNA Recombinante/administração & dosagem , DNA Recombinante/genética , Vírus Defeituosos/genética , Vírus Defeituosos/patogenicidade , Vírus Defeituosos/fisiologia , Vetores Genéticos/genética , Humanos , Mamíferos/virologia , Neoplasias/etiologia , Plasmídeos/genética , Proteínas Recombinantes/genética , Recombinação Genética , Retroviridae/genética , Retroviridae/patogenicidade , Retroviridae/fisiologia , Infecções Tumorais por Vírus/transmissão , Vacinação/efeitos adversos , Vacinação/tendências , Vacinas Sintéticas/efeitos adversos , Vacinas Sintéticas/classificação , Vacinas Virais/efeitos adversos , Vacinas Virais/classificação , Virulência , Replicação ViralRESUMO
The development of recombinant vector vaccines will be guided by nearly two centuries of research in vaccinology and immunology. Experimental vector vaccines may be of viral, bacterial or genetic composition and their acceptability will depend on safety, efficacy, and practicality as seen by the user, the developer, and the licensing authority. Recombinant vector vaccines will need to compete with alternative vaccine approaches and may find special use for non-propagable agents, immunization in early life, fertility control, and emerging infectious agents. Needs of the developing nations that include low cost, temperature stability, and ease of administration may be met, in part at least, by the vector vaccine approach.
Assuntos
Vetores Genéticos , Vacinas Sintéticas , Formação de Anticorpos , Células Apresentadoras de Antígenos/imunologia , Antígenos/imunologia , Vacinas Bacterianas/imunologia , Pré-Escolar , DNA Recombinante/administração & dosagem , Países em Desenvolvimento , Humanos , Imunidade Celular , Imunidade Materno-Adquirida , Lactente , Recém-Nascido , Segurança , Subpopulações de Linfócitos T/imunologia , Vacinação/economia , Vacinação/métodos , Vacinas Sintéticas/efeitos adversos , Vacinas Sintéticas/classificação , Vacinas Sintéticas/imunologia , Vacinas Virais/imunologiaRESUMO
The genes encoding the A (toxic) subunit of cholera toxin were deleted from pathogenic Vibrio cholerae O1 strain 569B by recombinant techniques, leaving intact production of immunogenic, non-toxic B subunit. The resultant strain, CVD 103, evaluated for safety, immunogenicity, and efficacy as a live oral vaccine, was highly attenuated and elicited strong antibacterial and antitoxic immune responses; a single dose significantly protected volunteers against challenge with pathogenic V cholerae O1 of either serotype or biotype. A further derivative, CVD 103-HgR, which has an Hg++-resistance gene to differentiate it from wild-type vibrios, was also well-tolerated, immunogenic, and protective; moreover, faecal excretion of this derivative was significantly lower than that of CVD 103, which should minimise environmental spread of the vaccine. CVD 103-HgR is a candidate for expanded clinical trials in endemic areas.